Switch to Europe/Worldwide website Switch to German website Switch to French website Switch to OriGene Technologies, Inc. (North America)
Home » Antibodies

Antibodies

(reset)
  1. Quick-Filters:
  2. Cited (26)
  3. Highly Validated (4)

Items 1 to 20 of 62 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4

Primary Antibodies

Catalog No. Host Iso. Clone Pres. React. Applications  

BETVIA allergen Bet v1 antibody
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG2 H.G27E9B1 Purified Pollen E, IP
0.1 mg / €600.00
  Dendritics SAS

BETVIA antibody
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG3 H.G26F6B2.06 Purified Pollen E
0.1 mg / €600.00
  Dendritics SAS

BETVIA antibody
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG4 H.G11A9F3.03 Purified Pollen E
0.1 mg / €600.00
  Dendritics SAS

BETVIA antibody
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG4 H.G28C10.01 Purified Pollen E
0.1 mg / €600.00
  Dendritics SAS

BETVIA antibody
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG1 H.G5F2A4.09 Purified Pollen E, WB
0.1 mg / €600.00
  Dendritics SAS

BETVIA antibody
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG2 H.G3A3C2.04 Purified Pollen E
0.1 mg / €600.00
  Dendritics SAS

CD49b / ITGA2 antibody
CD49b / ITGA2 Human IgG1 B4F12 Alexa Fluor 488 Hu F, ICC/IF
0.1 mg / €730.00
  Dendritics SAS

CD49b / ITGA2 antibody
CD49b / ITGA2 Human IgG1 B4F12 Alexa Fluor 647 Hu F, ICC/IF
0.1 mg / €730.00
  Dendritics SAS

CD49b / ITGA2 antibody
CD49b / ITGA2 Human IgG1 B4F12 Biotin Hu E, F
0.1 mg / €680.00
  Dendritics SAS

CD49b / ITGA2 antibody
IF staining of human platelets with B4F12 Human IgG1 B4F12 Purified Hu E, F, ICC/IF
0.1 mg / €600.00
  Dendritics SAS
+2 additional images

Chikungunya antibody
IF staining of OPY4 - infected VERO cells Human IgG1 E04C1.02 Purified Hu ICC/IF, NEUT
1 mg / €1,130.00
  Dendritics SAS
+1 additional image

Chikungunya antibody
IF staining of OPY4 - infected VERO cells Human IgG1 E04C1.02 Purified Hu ICC/IF, NEUT
0.1 mg / €600.00
  Dendritics SAS
+1 additional image

Chikungunya virus antibody
Immunofluorescent staining of VERO cells with E26D9 Human IgG1 E26D9 Purified Hu ICC/IF, NEUT
1 mg / €1,130.00
  Dendritics SAS
+2 additional images

Chikungunya virus antibody
Immunofluorescent staining of VERO cells with E26D9 Human IgG1 E26D9 Purified Hu ICC/IF, NEUT
0.1 mg / €600.00
  Dendritics SAS
+2 additional images

Chikungunya virus antibody
Immunofluorescent staining of VERO cells with E26C4 Human IgG1 E26C4 Purified Hu ICC/IF, NEUT
1 mg / €1,130.00
  Dendritics SAS
+1 additional image

Chikungunya virus antibody
Immunofluorescent staining of VERO cells with E26C4 Human IgG1 E26C4 Purified Hu ICC/IF, NEUT
0.1 mg / €600.00
  Dendritics SAS
+1 additional image

Chimaeric Human IgE anti Nitrophenyl-hapten (NP) antibody
Chimaeric Human IgE anti Nitrophenyl-hapten (NP) Human IgE JW8/1 Supernatant E
2 ml / €960.00
  OriGene Technologies GmbH

Chimaeric Human IgG2 anti Nitrophenyl-hapten (NP) antibody
Chimaeric Human IgG2 anti Nitrophenyl-hapten (NP) Human IgG2 JW183 Purified Hu E
0.5 mg / €560.00
  OriGene Technologies GmbH

Chimaeric human IgM anti Nitrophenyl-hapten (NP) antibody
Chimaeric human IgM anti Nitrophenyl-hapten (NP) Human IgM THM Supernatant E
2 ml / €770.00
  OriGene Technologies GmbH

Dystonin antibody
Dystonin Human IgG1 H5E.Hy.4B Purified Hu C, ICC/IF, WB
0.1 mg / €600.00
  Dendritics SAS

Items 1 to 20 of 62 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
62 products - FILTER YOUR RESULTS!

Active Filters

  1. Remove This Filter Host: Human
Clear All Filters

Available Filters

Product Type
  1. Isotype Control (28)
  2. Primary Antibody (34)
Clonality
  1. Monoclonal (34)
  2. Polyclonal (28)
Target
  1. BETVIA (6)
  2. CD49b / ITGA2 (4)
  3. Chikungunya (2)
  4. Chikungunya virus (4)
  5. Chimaeric Human IgE anti Nitrophenyl-hapten (NP) (1)
  6. Chimaeric Human IgG2 anti Nitrophenyl-hapten (NP) (1)
  7. Chimaeric human IgM anti Nitrophenyl-hapten (NP) (1)
  8. Dystonin (2)
  9. HPA-5b (5)
  10. Human IgA Isotype Control (4)
  11. Human IgE Isotype Control (4)
  12. Human IgG1 Isotype Control (4)
  13. Human IgG2 Isotype Control (4)
  14. Human IgG3 Isotype Control (3)
  15. Human IgG3 Isotype ontrol (1)
  16. Human IgG4 Isotype Control (4)
  17. Human IgM Isotype Control (4)
  18. Interleukin-1 alpha / IL-1A (5)
  19. Peptidase 1 / DERP1 (3)
Property
  1. allergen Bet v1 (1)
Reactivity
  1. Human (Hu) (23)
  2. Pollen (6)
Applications
  1. Immunocytochemistry/​Immunofluorescence (ICC/IF) (43)
  2. Flow cytometry (F) (37)
  3. Enzyme Immunoassay (E) (16)
  4. Frozen sections (C) (9)
  5. Neutralisation (NEUT) (7)
  6. Western blot / Immunoblot (WB) (6)
  7. Immunoprecipitation (IP) (1)
  8. Paraffin Sections (P) (1)
Presentation
  1. Purified (28)
  2. Alexa 488 (6)
  3. Alexa 546 (6)
  4. Alexa 647 (6)
  5. Alexa Fluor 488 (4)
  6. Alexa Fluor 647 (4)
  7. Alexa Fluor 546 (3)
  8. Biotin (3)
  9. Supernatant (2)
Images
  1. 1 image (29)
  2. 3+ images (12)
Images: Applications
  1. Immunocytochemistry/​Immunofluorescence (ICC/IF) (12)
  2. Enzyme Immunoassay (E) (8)
  3. Neutralisation (NEUT) (6)
  4. Flow cytometry (F) (5)
  5. Functional assay (FN) (5)
Manufacturer
  1. Dendritics SAS (59)
  2. OriGene Technologies (3)
Service
  • OriGene Technologies GmbH
  • Schillerstraße 5
  • D-32052 Herford
  • Germany
  • phone: +49-5221-34606-0
  • free call: 0800-227 47 46 (Germany only)
  • fax: +49-5221-34606-11
  • email: info-de@origene.com
  • orders: ordering-de@origene.com
 
© Copyright 1998 - 2018 OriGene Technologies GmbH
  • LinkedIn